Cynata Therapeutics Limited
CYYNF
$0.118
$0.01615.69%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 641.90K | 660.00K | -75.80K | -75.70K | 829.50K |
| Total Revenue | 641.90K | 660.00K | -75.80K | -75.70K | 829.50K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 641.90K | 660.00K | -75.80K | -75.70K | 829.50K |
| SG&A Expenses | 1.48M | 1.53M | -1.28M | -1.28M | 1.97M |
| Depreciation & Amortization | 44.50K | 45.80K | 46.20K | 46.20K | 45.70K |
| Other Operating Expenses | 303.10K | 311.70K | 174.60K | 174.30K | 290.70K |
| Total Operating Expenses | 1.83M | 1.88M | 1.80M | 1.80M | 2.31M |
| Operating Income | -1.19M | -1.22M | -1.87M | -1.87M | -1.48M |
| Income Before Tax | -1.19M | -1.22M | -1.71M | -1.71M | -1.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.19M | -1.22M | -1.71M | -1.71M | -1.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.19M | -1.22M | -1.71M | -1.71M | -1.48M |
| EBIT | -1.19M | -1.22M | -1.87M | -1.87M | -1.48M |
| EBITDA | -1.14M | -1.18M | -1.83M | -1.82M | -1.43M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 184.33M | 184.33M | 179.77M | 179.77M | 179.49M |
| Average Diluted Shares Outstanding | 184.33M | 184.33M | 179.77M | 179.77M | 179.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |